The four-protein signature is associated with early forms of colon cancer that are most likely to progress into later stages of the disease.
The company said it will use part of the proceeds to repurchase some of its senior notes due in January 2025, and the rest for corporate purposes.
The company said test volume for its Cologuard colorectal cancer test rose 66 percent during the quarter to 292,000.
The startup, which was founded by two Washington University researchers and a Wharton MBA, is looking to take a big bite out of Cologuard's market.
The test, which searches for fragments of DNA 200 basepairs or longer that are characteristic of diseased mucosa, may eventually compete with diagnostics like Exact Sciences' Cologuard.
The 360Dx Index was up 12 percent last month as shares of Accelerate Diagnostics, Veracyte, and Exact Sciences each improved more than 40 percent month over month.
Abbott CEO Miles White is bullish on the firm's Alinity systems, while Quest and LabCorp see acquisitions as the likely result of further PAMA-related cuts.
The company said it completed approximately 292,000 Cologuard tests during the fourth quarter.
Test volume for the firm's Cologuard colorectal cancer screening test rose 49 percent year over year during the quarter.
Biomatrica's sample collection tubes ensure quality preservation of circulating tumor DNA and cells, promoting high-quality liquid biopsy results, Exact said.